Janine Mahoney

484 total citations
17 papers, 330 citations indexed

About

Janine Mahoney is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Janine Mahoney has authored 17 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Physiology. Recurrent topics in Janine Mahoney's work include Respiratory and Cough-Related Research (6 papers), Voice and Speech Disorders (6 papers) and HER2/EGFR in Cancer Research (5 papers). Janine Mahoney is often cited by papers focused on Respiratory and Cough-Related Research (6 papers), Voice and Speech Disorders (6 papers) and HER2/EGFR in Cancer Research (5 papers). Janine Mahoney collaborates with scholars based in United States, Australia and South Korea. Janine Mahoney's co-authors include Yasir M. Nagarwala, Mark Hew, Anne E. Vertigan, Jennifer Oates, Scott K. Pruitt, Do‐Youn Oh, Makoto Ueno, Lu Xu, Robin Kate Kelley and Aurélien Marabelle and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Annals of Oncology.

In The Last Decade

Janine Mahoney

15 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janine Mahoney United States 10 193 162 85 76 50 17 330
Zhengping Ding China 12 118 0.6× 200 1.2× 42 0.5× 161 2.1× 20 0.4× 26 431
Dominique Rosine France 7 149 0.8× 154 1.0× 59 0.7× 72 0.9× 10 0.2× 9 311
D.H. Lee South Korea 6 261 1.4× 112 0.7× 26 0.3× 63 0.8× 28 0.6× 16 386
Ina Valeria Zurlo Italy 6 105 0.5× 89 0.5× 42 0.5× 36 0.5× 19 0.4× 24 191
Keita Uchino Japan 12 215 1.1× 151 0.9× 59 0.7× 86 1.1× 28 0.6× 40 357
Takeshi Kawakami Japan 8 169 0.9× 190 1.2× 118 1.4× 41 0.5× 8 0.2× 67 333
Matthias Schauer Germany 10 114 0.6× 178 1.1× 141 1.7× 95 1.3× 5 0.1× 24 332
Hiromichi Shirasu Japan 10 232 1.2× 168 1.0× 96 1.1× 58 0.8× 5 0.1× 32 395
James P. De Andrade United States 12 134 0.7× 100 0.6× 70 0.8× 195 2.6× 29 0.6× 25 400
Grillo Ruggieri F Italy 11 123 0.6× 145 0.9× 81 1.0× 30 0.4× 43 0.9× 33 334

Countries citing papers authored by Janine Mahoney

Since Specialization
Citations

This map shows the geographic impact of Janine Mahoney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Mahoney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Mahoney more than expected).

Fields of papers citing papers by Janine Mahoney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Mahoney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Mahoney. The network helps show where Janine Mahoney may publish in the future.

Co-authorship network of co-authors of Janine Mahoney

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Mahoney. A scholar is included among the top collaborators of Janine Mahoney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Mahoney. Janine Mahoney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Denton, Eve, Janine Mahoney, Stephanie Stojanovic, et al.. (2025). Significance of Inducible Laryngeal Obstruction Phenotypes Identified by Latent Class Analysis. The Journal of Allergy and Clinical Immunology In Practice. 13(10). 2817–2825.e2. 1 indexed citations
2.
Lim, Sun Min, Jianjun Zhang, Nir Peled, et al.. (2025). 58P: Subcutaneous (SC) after intravenous (IV) amivantamab in advanced NSCLC: Initial results from PALOMA-2. Journal of Thoracic Oncology. 20(3). S46–S47.
3.
Mahoney, Janine, Mark Hew, Anne E. Vertigan, et al.. (2025). Amitriptyline Versus Placebo in Addition to Speech Pathology for Inducible Laryngeal Obstruction: A Double-blind Randomised Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A7775–A7775.
4.
Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612. 3 indexed citations
5.
Denton, Eve, Brigitte M. Borg, Janine Mahoney, et al.. (2024). Investigation of exertional dyspnoea by cardiopulmonary exercise testing with continuous laryngoscopy. Journal of science and medicine in sport. 28(2). 95–100. 1 indexed citations
6.
Mahoney, Janine, Anne E. Vertigan, Mark Hew, & Jennifer Oates. (2024). Exploring Factors Impacting Engagement in Speech Pathology Intervention for Inducible Laryngeal Obstruction. Journal of Voice. 4 indexed citations
7.
Pham, Jonathan, Eve Denton, Joy Lee, et al.. (2023). Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment. Allergy. 78(9). 2418–2427. 9 indexed citations
8.
Shu, Catherine A., Kōichi Goto, Benjamin Besse, et al.. (2022). Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.. Journal of Clinical Oncology. 40(16_suppl). 9006–9006. 39 indexed citations
9.
Stojanovic, Stephanie, Eve Denton, Joy Lee, et al.. (2021). Diagnostic and Therapeutic Outcomes Following Systematic Assessment of Patients with Concurrent Suspected Vocal Cord Dysfunction and Asthma. The Journal of Allergy and Clinical Immunology In Practice. 10(2). 602–608.e1. 17 indexed citations
10.
Mahoney, Janine, Mark Hew, Anne E. Vertigan, & Jennifer Oates. (2021). Treatment effectiveness for Vocal Cord Dysfunction in adults and adolescents: A systematic review. Clinical & Experimental Allergy. 52(3). 387–404. 32 indexed citations
11.
Shu, Catherine A., Kōichi Goto, Byoung Chul Cho, et al.. (2021). CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.. Journal of Clinical Oncology. 39(15_suppl). TPS9132–TPS9132. 18 indexed citations
12.
Ueno, Makoto, Hyun Cheol Chung, Adnan Nagrial, et al.. (2018). Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study. Annals of Oncology. 29. viii210–viii210. 59 indexed citations
13.
Chew, Helen K., Lee S. Schwartzberg, Suprith Badarinath, et al.. (2014). Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer. SpringerPlus. 3(1). 108–108. 2 indexed citations
14.
Holmes, Frankie A., Virginia Espina, Lance A. Liotta, et al.. (2013). Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes. 6(1). 507–507. 50 indexed citations
15.
Yardley, Denise A., Lowell L. Hart, Linda D. Bosserman, et al.. (2012). Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Research and Treatment. 137(2). 457–464. 33 indexed citations
16.
Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations
17.
Galsky, Matt D., Daniel D. Von Hoff, M. Neubauer, et al.. (2009). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3541–3541. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengping Ding Breakdown of academic impact, for papers by Dominique Rosine Breakdown of academic impact, for papers by D.H. Lee Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Keita Uchino Breakdown of academic impact, for papers by Takeshi Kawakami Breakdown of academic impact, for papers by Matthias Schauer Breakdown of academic impact, for papers by Hiromichi Shirasu Breakdown of academic impact, for papers by James P. De Andrade Breakdown of academic impact, for papers by Grillo Ruggieri F
Rankless by CCL
2026